Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth
factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, eg …

Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a
comprehensive understanding of CAFs' functional distinctions, it remains unclear how …

First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major
clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung …

Purpose: To identify molecular factors that determine duration of response to EGFR tyrosine
kinase inhibitors and to identify novel mechanisms of drug resistance, we molecularly …

Lung cancer is the leading cause of cancer related deaths in Canada with non-small cell
lung cancer (NSCLC) being the predominant form of the disease. Tumor characterization …

Abstract Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of
Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently …